Photo: BasPhoto / Shutterstock.com
AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, AstraZeneca, mergers and acquisitions, oncology